Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study

BACKGROUND: Platinum-based drugs are used as cancer chemotherapeutics for the last 40 years. However, drug resistance and nephrotoxicity are the major limitations of the use of platinum-based compounds in cancer therapy. Platinum (IV) complexes are believed to act as platinum prodrugs and are able t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ratzon, Einav, Najajreh, Yousef, Salem, Rami, Khamaisie, Hazem, Ruthardt, Martin, Mahajna, Jamal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763415/
https://www.ncbi.nlm.nih.gov/pubmed/26906901
http://dx.doi.org/10.1186/s12885-016-2182-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763415/
https://www.ncbi.nlm.nih.gov/pubmed/26906901
http://dx.doi.org/10.1186/s12885-016-2182-8

Ejemplares similares